Sharing results from a real-world single center study of patients with diabetic macular oedema (DMO) who wore a home-use sleep mask (Noctura 400) for 12 months
PolyPhotonix, the manufacturer of the Noctura 400 – a treatment for diabetic retinopathy – recently completed a realworld study at an NHS hospital in the UK, which began in 2019. The study analyzed the effects of enhanced patient interaction with and use of the Noctura 400 sleep mask in a group of 26 diabetics displaying diabetic retinopathy (DR) and diabetic macular oedema (DMO). The results of the study were remarkable: 94 percent of the patients who completed the study saw clinical improvement or stability. But the results are even more impressive when considering that the patients taking part in the study were a vulnerable population advised by the UK government and the NHS not to attend hospital for treatment during the COVID-19 pandemic.